Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;17(5):41.
doi: 10.1007/s11910-017-0751-0.

Multiple System Atrophy - State of the Art

Affiliations
Review

Multiple System Atrophy - State of the Art

Brice Laurens et al. Curr Neurol Neurosci Rep. .

Abstract

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder that is characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. Some symptomatic treatments are available while neuroprotection or disease-modification remain unmet treatment needs. The pathologic hallmark is the accumulation of aggregated alpha-synuclein (α-syn) in oligodendrocytes forming glial cytoplasmic inclusions, which qualifies MSA as synucleinopathy together with Parkinson's disease and dementia with Lewy bodies. Despite progress in our understanding of the pathogenesis of MSA, the origin of α-syn aggregates in oligodendrocytes is still a matter of an ongoing debate. We critically review here studies published in the field over the past 5 years dealing with pathogenesis, genetics, clinical signs, biomarker for improving diagnostic accuracy, and treatment development.

Keywords: Alpha-synuclein; Atypical parkinsonism; MSA; Oligodendrocyte.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Neurobiol Aging. 2016 Sep;45:213.e1-213.e2 - PubMed
    1. N Engl J Med. 2014 Jul 3;371(1):80-1 - PubMed
    1. PLoS One. 2014 Dec 29;9(12):e116123 - PubMed
    1. Nature. 2015 Jun 18;522(7556):340-4 - PubMed
    1. Brain. 2009 Jul;132(Pt 7):1810-9 - PubMed

MeSH terms

LinkOut - more resources

Feedback